WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced data from a Phase 1 trial with ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, demonstrating that treatment with ARQ 197 was very well tolerated over extended dosing periods, with more than 60 percent of patients experiencing partial responses, minor responses or stable disease. Findings resulted in a recommended Phase 2 dose of 240 milligrams (mg) daily.
